Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions

Molecular and Cellular Biology

Volumn 21, Issue 15, 2001, Pages 4909-4918

  Osburn, D L ^a   Shao, G ^a   Seidel, H M ^a   Schulman, I G ^a  

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CELLS, CULTURED; DIMERIZATION; ENZYME ACTIVATION; LIGANDS; MUTATION; PLASMIDS; PRECIPITIN TESTS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, RETINOIC ACID; RECEPTORS, THYROID HORMONE; RETINOID X RECEPTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UBIQUITINS;

ANIMALIA;

EID: 0034958787     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.15.4909-4918.2001     Document Type: Article

References (70)

1. Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases
2. Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation
3. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids
4. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells
5. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes
6. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha
7. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains
8. Identification of the first retinoid X receptor homodimer antagonist
9. A transcriptional co-repressor that interacts with nuclear hormone receptors
10. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway
11. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody
12. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors
13. Functional inhibition of retinoic acid response by dominant negative retinoic receptor mutants
14. Structure and specificity of nuclear receptor-coactivator interactions
15. Endogenous retinoid X receptors can function as hormone receptors in pituitary cells
16. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
17. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid
18. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors
19. Unique response pathways are established by allosteric interactions among nuclear hormone receptors
20. A c-erb-A binding site in rat growth hormone gene mediates trans-activation by thyroid hormone
21. Nuclear receptor coactivators
22. The coregulator exchange in transcriptional functions of nuclear receptors
23. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation
24. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
25. In vivo degradation of a transcriptional regulator: The yeast alpha 2 repressor
26. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors
27. Oncoprotein networks
28. Regulation of transcription by ubiquitination without proteolysis: Cdc34/SCF(Met30)-mediated inactivation of the transcription factor Met4
29. Different agonist-and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping
30. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway
31. Lessons from hereditary colorectal cancer
32. Dimerization with RXRs and phosphorylation modulate the retinoic acid- induced degradation of RARα and RARγ and through the ubiquitin-proteasome pathway
33. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding
34. Activation of specific RXR heterodimers by an antagonist of RXR homodimers
35. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome
36. Ligand-induced alteration of the protease sensitivity of retinoid X receptorα
37. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation
38. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid
39. The RXR heterodimers and orphan receptors
40. The nuclear receptor superfamily: The second decade
41. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
42. Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo
43. The nuclear receptor ligand-binding domain: Structure and function
44. Mechanism of corepressor binding and release from nuclear hormone receptors
45. Proteasome-dependent degradation of the human estrogen receptor
46. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
47. 9-cis-Retinoic acid decreases the level of its cognate receptor, retinoid X receptor, through acceleration of the turnover
48. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin
49. Molecular determinants of nuclear receptor-corepressor interaction
50. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator: Coactivator interactions
51. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
52. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis
53. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells
54. Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation
55. Activation and repression by nuclear hormone receptors: Hormone modulates an equilibrium between active and repressive states
56. The phantom ligand effect: Allosteric control of transcription by the retinoid X receptor
57. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARγ) heterodimers: Intermolecular synergy requires only the PPARγ hormone-dependent activation function
58. Three amino acids specify coactivator choice by retinoid X receptors
59. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
60. Induced alpha helix in the VP16 activation domain upon binding to a human TAF
61. Retinoic acid and thyroid hormone induce gene expression through a common responsive element
62. How cancer arises
63. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells
64. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators
65. Heterodimeric interaction between retinoid X receptor α and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation
66. Receptor-selective retinoid agonists and teratogenic activity
67. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E
68. A canonical structure for the ligand-binding domain of nuclear receptors
69. A novel role for helix 12 of retinoid X receptor in regulating repression
70. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARα) and oncogenic RARα fusion proteins